ReviewAnnals of thoracic medicine
Continuous renal replacement therapy combined with ulinastatin in acute respiratory distress syndrome: A systematic review and meta-analysis.
Review in Annals of thoracic medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) is a severe clinical condition with high mortality, and effective adjunctive therapies remain limited. In recent years, continuous renal replacement therapy (CRRT) and ulinastatin have both been applied in ARDS management, but the clinical value of their combined use is still unclear. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy of CRRT combined with ulinastatin compared with CRRT alone in patients with ARDS. A comprehensive search of 11 English and Chinese databases was performed from inception to August 29, 2025. Randomized controlled trials enrolling adult patients with ARDS and comparing CRRT plus ulinastatin versus CRRT alone were included. Mortality was the primary outcome, and secondary outcomes included intensive care unit (ICU) length of stay, mechanical ventilation time (MVT), Acute Physiology and Chronic Health Evaluation II (APACHE II) score at 7 days, oxygenation index (OI) at 7 days, and partial pressure of oxygen (PaO₂) at 7 days. Five studies involving 384 patients met the inclusion criteria. Pooled analysis showed that combination therapy significantly reduced mortality (risk ratio [RR] = 0.37, 95% confidence interval [CI] 0.23-0.60), ICU length of stay, MVT, and APACHE II scores at 7 days, and significantly improved OI and PaO₂ at 7 days compared with CRRT alone. Overall, current evidence of limited quality suggests that CRRT combined with ulinastatin may improve short-term clinical outcomes in patients with ARDS. Future rigorous, large-scale, multicenter randomized controlled trials are essential to verify these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.